Comment from American Academy of Dermatology Association (AADA)

Summary: The American Academy of Dermatology Association (AADA) supports the FDA's pilot program for AI-enabled optimization of early-phase clinical trials, provided it includes specific safeguards for data quality, safety, and transparency. They urge the FDA to include dermatology in the pilot, involve dermatologists and patients in AI governance, and ensure that AI tools are used to reduce administrative burdens rather than creating new ones.